AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 222 min read$CLDX

Celldex's Barzolvolimab Meets Phase 3 Goals In Chronic Hives Studies; Stock Down

Celldex (CLDX) reported positive Phase 3 results for Barzolvolimab in chronic hives studies, meeting primary and secondary endpoints. The drug showed rapid and sustained efficacy, with plans to submit a Biologics License Application in 2027. CLDX stock is down 16.57% to $31.67.

Original reporting
rttnews.com
Published Sep 22, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 5:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Celldex's Barzolvolimab Meets Phase 3 Goals In Chronic Hives Studies; Stock Down — source image
Source · rttnews.com
Decision brief

The 30-second read

$CLDXBullishMed
01

Why it matters

Positive Phase 3 results are a key value inflection point for CLDX, likely to attract analyst upgrades and institutional buying.

02

Market read

First‑report of pivotal trial success; material for traders targeting biotech catalysts.

03

What to watch

Regulatory timeline (BLA filing in 2027) and potential need for larger Phase 3 confirmatory study.

Relevance 9/10Novelty 9/10Timing: today

Background

Celldex (CLDX) is a clinical‑stage biotech focused on immunology. The company plans a BLA filing in 2027.

Company-level read

Ticker impact

$CLDXBullishHigh confidence
Context

Celldex reported positive Phase 3 trial results for Barzolvolimab in chronic spontaneous urticaria.

Expected impact

Potential upside of 10‑15% over the next 2‑4 weeks if data is confirmed by analysts.

Evidence & confidence

Phase 3 success is a material catalyst for a biotech; the stock is already down on the news, suggesting a short‑term oversell that may reverse.

Market effects

Sector

Strengthens the chronic hives therapeutic space and may boost peer biotech valuations.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

The data may not translate into commercial success; reimbursement and competition could limit upside.

Key entities

  • company
    Celldex Therapeutics

    Biotech developing Barzolvolimab for chronic spontaneous urticaria.

Read at source← All news

Related articles

SEP 22
$CLDXMedAI 9/10

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Celldex Therapeutics (CLDX) stock fell 11% despite positive Phase 3 trial results for Barzolvolimab, its treatment for chronic spontaneous urticaria. H.C. Wainwright raised its price target to $64, citing nearly 90% upside potential. The studies met primary and secondary endpoints, but safety concerns, including two cases of probable Grade 4 anaphylaxis, led to the initial sell-off. Celldex plans to file for FDA approval in 2027.

stocktwits.com2 min
SEP 22
$CLDXMedAI 8/10

Why is Celldex Therapeutics stock plummeting today?

Celldex Therapeutics (CLDX) stock fell 37% in pre-market trading after positive Phase 3 trial results for barzolvolimab, a 'sell the news' reaction. The trials met primary and secondary endpoints, but investors were disappointed, as the stock had rallied ahead of the announcement. The company's Phase 2 study failure and delayed BLA submission also contributed to the decline. The broader market showed little impact, indicating the drop was company-specific.

investing.com2 min
SEP 22
$CLDXHighAI 9/10

Celldex stock rises after positive phase 3 trial results

Celldex Therapeutics (CLDX) shares rose 8% after reporting positive Phase 3 trial results for barzolvolimab in treating chronic spontaneous urticaria (CSU). Both trials met primary and secondary endpoints, showing significant improvements in disease activity. The 150 mg and 300 mg doses outperformed placebos, with complete response rates of 42.4%-54.0% versus 9.3%-12.6%. The drug was well-tolerated, and Celldex plans an FDA submission in 2027.

investing.com2 min